Cancer
Cancer Ongoing 2021 NSW, QLD, SA

TRIDENT

Pivotal randomized, open-label study of optune® (ttfields, 200khz) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma.

Trial overview

Disease
Brain and spine cancer
Topic
TRIDENT
Eligibility criteria
  • New diagnosis of Glioblastoma (GBM) 
  • >18 years old 
  • Recovered from debulking surgery (total, paritial or biopsy-only acceptable) 
  • Planned treatment with Temozolomide (TMZ) and Radiotherapy (RT) followed by ttfields and maintenance TMZ 
  • Stable or decreasing dose of corticosteroids 
  • Able to have MRI with Contrast 
Study details

The purpose of the study is to test if early addition of the Optune®treatment combined with RT and TMZ as treatment for newly diagnosed GBM, significantly improves the clinical outcome of patients, compared to the standard of care, which is addition of Optune®treatment concomitant with maintenance temozolomide after the completion of RT treatment.

Further information

For more information regarding this clinical trial click here.

Location

NSW, QLD, SA